Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Avera and Avera Health Plans transitioned to a new combined patient and member portal as of May 30, 2026. If you haven’t already, create an account and reset your proxy access. Learn how to sign up at Avera.org/MyChart.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (5)

Showing 1-5 of 5

Sorted By:

A-Z
Z-A

Previous Next

bb2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information.
S1803: Phase III Study of Daratumumab/rHuPH20 (NSC – 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Meyloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2.
S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Ph. III Rand. Trial for New Diagnosed Multiple Myeloma Pts Considered Frail/Subset of "Interm. Fit" Comparing Upfront 3-Drug Induct. Regimens Followed by Dbl/Sing-Agent Maint.
S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Ph. III Rand. Trial for New Diagnosed Multiple Myeloma Pts Considered Frail/Subset of "Interm. Fit" Comparing Upfront 3-Drug Induct. Regimens Followed by Dbl/Sing-Agent Maint.
SWOG S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Ph. III Rand. Trial for New Diagnosed Multiple Myeloma Pts Considered Frail/Subset of "Interm. Fit" Comparing Upfront 3-Drug Induct. Regimens Followed by Dbl/Sing-Agent Maint.

Previous Next